Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Don't Lose Track: Review And Approval News On Opdivo, Kalydeco And More

Executive Summary

US FDA had a busy week. Here's some bullet points of product development events you may have missed.

You may also be interested in...

Heplisav Postmarketing Worries Push PDUFA Date Back; FDA Seeks More Details

Dynavax's final pivotal trial for hepatitis B candidate was missing data from 150 patients, making its causality of myocardial infarctions unclear; the question now is whether the postmarketing trial can answer the question.

BMS' Opdivo Approval In CRC Overshadowed By Keytruda Dominance

The US FDA has approved BMS' Opdivo for previously treated patients with some forms of colorectal cancer, however direct competition from Merck's Keytruda may limit its success.

Celltrion's Herceptin Biosimilar One Step Closer To US FDA Approval

Following Oncologic Drugs Advisory Committee's recommendation for Mylan and Biocon's trastuzumab biosimilar, Celltrion and Teva's CT-P6 appear to be one of the next one in, but given the expiry of Herceptin patent in the US and other late stage trastuzumab biosimilar candidates, it could be anybody's game to launch their products first.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts